CureGene Pharmaceutical (“CureGene”) announces that the dosing for its in-house developed next-generation antiplatelet drug, Evategrel with both intravenous injection and oral administration, has been  completed for Phase I clinical trial in China. The drug demonstrated excellent platelet inhibition and high safety windows with all end points meeting expectations. This marks a significant milestone in the development of this innovative drug in China, bringing new hope for future clinical applications and patient treatment.

In recent years, cardio-cerebrovascular disease has become one of the leading causes of death worldwide. Among them, coronary artery disease (CAD) is the most common type of cardiovascular disease, with nearly 10 million deaths annually due to acute and chronic coronary syndromes and a patient population reaching hundreds of millions, posing a severe threat to human health and life. To prevent and treat coronary heart disease, antiplatelet drugs play a critical role in clinical management and prevention of cardio-cerebrovascular diseases.

As an innovative pharmaceutical company focused on cardio-cerebrovascular, obesity, and antiviral areas, CureGene is catalyzing the clinical development of evategrel through its robust R&D capabilities and innovative platform technologies. We look forward to this groundbreaking drug benefiting more patients and creating more value for society.

CG-0255 is a revolutionary antiplatelet drug with truly unique and innovative design, it has been developed in two formulations: intravenous and oral. It is currently undergoing clinical development for indications such as acute coronary syndrome, recent myocardial infarction, recent stroke, and peripheral arterial disease to address the shortcomings of existing treatment options, unmet clinical needs, and to provide better antiplatelet solutions for all patients. CG-0255 has rapid onset of action, good safety profile, and shows minimal individual variations, overcoming widely present resistant issue with current treatment. CG-0255 also has little drug-drug interactions. It has the potential to become the best-in-class P2Y12antagonist antiplatelet drug and fully meet the clinical needs in various medication scenarios. 

CureGene was founded in 2018. Based in China, we strive to become a globally focused innovative biopharmaceutical company. We have established innovative platforms based on our core expertise and capability. Currently we are focused on cardio-cerebrovascular and antiviral disease areas. We have developed a number of pipelines of drugs with huge market potential and fully owned global IP rights and are actively moving these projects forward. Guided by our shared mission statement, we have assembled a group of talented and highly accomplished scientists with global pharmaceutical experience from China and overseas. With a comprehensive strategic vision, CureGene has successfully and highly efficiently moved from research stage startup into a clinical stage company, with all pipelines capable of First-in-Class or Best-in-Class potential.